Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Memphasys Ltd ( (AU:MEM) ).
Memphasys Limited has secured a $472,236 loan against its 2024/25 R&D Tax Rebate to support the commercial activities of its FelixTM System following the completion of clinical trials and CE Mark registration. The loan, which carries a 15% annual interest rate and is repayable from the expected $900k R&D Tax Rebate in September 2025, will also aid in managing the company’s working capital requirements, reflecting Memphasys’ strategic approach to funding its development portfolio.
More about Memphasys Ltd
Memphasys Limited is an Australian reproductive biotechnology company focused on developing and commercializing advanced reproductive technologies, including the FelixTM System, which is designed to enhance fertility outcomes.
Average Trading Volume: 10,181,599
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$12.4M
Find detailed analytics on MEM stock on TipRanks’ Stock Analysis page.